TY - JOUR
T1 - A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)
AU - Du Bois, A.
AU - Belau, A.
AU - Wagner, U.
AU - Pfisterer, J.
AU - Schmalfeldt, B.
AU - Richter, B.
AU - Staehle, A.
AU - Jackisch, C.
AU - Lueck, H. J.
AU - Schroeder, W.
AU - Burges, A.
AU - Olbricht, S.
AU - Elser, G.
PY - 2005/2
Y1 - 2005/2
N2 - A multicenter, nonrandomized, phase II study was initiated to evaluate the tolerability, toxicity, and activity of paclitaxel, carboplatin, and gemcitabine combination in previously untreated ovarian cancer. Chemonaive patients who had radical debulking surgery for primary epithelial ovarian cancer International Federation of Gynecology and Obstetrics (FIGO) IC-IV received sequentially paclitaxel 175 mg/m2, carboplatin AUC 5, and gemcitabine 800 mg/m2 on day 1 and gemcitabine 800 mg/m2 on day 8, every 3 weeks. From October 2001 to July 2002, 55 patients were treated and evaluated. Main toxicities were hematological with NCI-CTC grade 3/4 anemia 12.7%, leukopenia 70.9%, neutropenia 76.3%, and thrombocytopenia 45.5. However, febrile neutropenia occurred only in 1.8%. Grade 3/4 nonhematological toxicities were rare and occurred in less than 10% of patients. Toxicity-induced treatment delays occurred in 3.1% of cycles and resulted in early treatment cessation in four patients. Dose intensity reached 90.8% for carboplatin and paclitaxel, and 73.3% for gemcitabine. Objective response was observed in 10 of 14 patients with measurable disease. The triplet combination of paclitaxel-carboplatin- gemcitabine is feasible and active, with manageable hematological toxicity and no unexpected nonhematological toxicity. This regimen has proceeded to phase III evaluation.
AB - A multicenter, nonrandomized, phase II study was initiated to evaluate the tolerability, toxicity, and activity of paclitaxel, carboplatin, and gemcitabine combination in previously untreated ovarian cancer. Chemonaive patients who had radical debulking surgery for primary epithelial ovarian cancer International Federation of Gynecology and Obstetrics (FIGO) IC-IV received sequentially paclitaxel 175 mg/m2, carboplatin AUC 5, and gemcitabine 800 mg/m2 on day 1 and gemcitabine 800 mg/m2 on day 8, every 3 weeks. From October 2001 to July 2002, 55 patients were treated and evaluated. Main toxicities were hematological with NCI-CTC grade 3/4 anemia 12.7%, leukopenia 70.9%, neutropenia 76.3%, and thrombocytopenia 45.5. However, febrile neutropenia occurred only in 1.8%. Grade 3/4 nonhematological toxicities were rare and occurred in less than 10% of patients. Toxicity-induced treatment delays occurred in 3.1% of cycles and resulted in early treatment cessation in four patients. Dose intensity reached 90.8% for carboplatin and paclitaxel, and 73.3% for gemcitabine. Objective response was observed in 10 of 14 patients with measurable disease. The triplet combination of paclitaxel-carboplatin- gemcitabine is feasible and active, with manageable hematological toxicity and no unexpected nonhematological toxicity. This regimen has proceeded to phase III evaluation.
KW - Carboplatin
KW - Chemotherapy
KW - Epithelial ovarian cancer
KW - Gemcitabine
KW - Paclitaxel
UR - http://www.scopus.com/inward/record.url?scp=19944431264&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2004.10.020
DO - 10.1016/j.ygyno.2004.10.020
M3 - Article
C2 - 15661234
AN - SCOPUS:19944431264
SN - 0090-8258
VL - 96
SP - 444
EP - 451
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -
